Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04286594 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial of a Hemp-Derived Cannabidiol Product for Anxiety
A Phase 2 study, sponsored by Mclean Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT04286594 is a Phase 2 study that was terminated before completion, run by Mclean Hospital. The registered enrollment target is 15 participants.
The verdict
NCT04286594, a Phase 2 study, was terminated before completion, sponsored by Mclean Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This open-label to double-blind study evaluates the impact of cannabidiol (CBD) on anxiety in adults. Participants will use a custom-formulated sublingual (under-the-tongue) solution of whole plant, hemp-derived CBD twice daily for six weeks in addition to their normal treatment regimen. Participants' clinical state will be assessed weekly during the treatment period. Quality of life, sleep, general health, and cognitive function will also be assessed.
Interventions
- DRUG CBD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2023-08-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04286594
The ClinicalTrials.gov registry entry for NCT04286594 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CBD is the first listed.
NCT04286594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04286594 about?
NCT04286594 is a clinical study titled "A Clinical Trial of a Hemp-Derived Cannabidiol Product for Anxiety". This open-label to double-blind study evaluates the impact of cannabidiol (CBD) on anxiety in adults. Participants will use a custom-formulated sublingual (under-the-tongue) solution of whole plant, hemp-derived CBD twice daily for six weeks in addition to their normal treatment regimen. Participant...
What is the current status of trial NCT04286594?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2021-02-01. Estimated completion is 2023-08-24.
What interventions are being tested in trial NCT04286594?
The interventions under investigation include: CBD (DRUG).
Who is sponsoring clinical trial NCT04286594?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.